APA (7th ed.) Citation

AV, D., MA, A., TG, K., A, O., C, Y., KR, B., . . . SL, C. (2022). Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. Cancer, 128(15), 2967. https://doi.org/10.1002/cncr.34263

Chicago Style (17th ed.) Citation

AV, Desai, et al. "Efficacy of Post-induction Therapy for High-risk Neuroblastoma Patients with End-induction Residual Disease." Cancer 128, no. 15 (2022): 2967. https://doi.org/10.1002/cncr.34263.

MLA (9th ed.) Citation

AV, Desai, et al. "Efficacy of Post-induction Therapy for High-risk Neuroblastoma Patients with End-induction Residual Disease." Cancer, vol. 128, no. 15, 2022, p. 2967, https://doi.org/10.1002/cncr.34263.